115 Publications (Page 2 of 5)
2016
Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
Weber, Jeffrey SGibney, Geoffrey ThomasSullivan, Ryan JSosman, Jeffrey AlanSlingluff, Craig LLawrence, Donald PLogan, Theodore FSchuchter, Lynn MaraNair, SureshBuchbinder, Elizabeth IannottiBerghorn, ElmerJiang, JoelHorak, Christine E and Hodi, F. Stephen
Journal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. 9517, 2016-05-20. | Journal Article
2015
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Bradish, Joshua RBradish, Joshua RBradish, Joshua RRichey, Justin DRichey, Justin DRichey, Justin DPost, Kristin MPost, Kristin MPost, Kristin MMeehan, KariMeehan, KariMeehan, KariSen, Joyashree DSen, Joyashree DSen, Joyashree DMalek, Amanda JMalek, Amanda JMalek, Amanda JKatona, Terrence MKatona, Terrence MKatona, Terrence MWarren, SimonWarren, SimonWarren, SimonLogan, Theodore FLogan, Theodore FLogan, Theodore FFecher, Leslie AFecher, Leslie AFecher, Leslie ACheng, LiangCheng, Liang and Cheng, Liang
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, vol. 28, (no. 4), pp. 480-486, April 2015. | Journal Article
 
Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)
Armstrong, Andrew JBroderick, SamuelEisen, TimStadler, Walter MichaelJones, Robert JGarcia, Jorge AVaishampayan, Ulka NPicus, JoelHawkins, Robert EHainsworth, John DKollmannsberger, Christian KLogan, Theodore FPuzanov, IgorPickering, Lisa MRyan, Christopher WProtheroe, AndrewLusk, Christine MOberg, SadieHalabi, Susan and George, Daniel J
Journal of Clinical Oncology, vol. 33, (no. 15_suppl), pp. 4507, 2015-05-20. | Journal Article
 
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer, Robert JRini, Brian IMc Dermott, David FRedman, Bruce GKuzel, Timothy MHarrison, Michael RVaishampayan, Ulka NDrabkin, Harry AGeorge, SabyLogan, Theodore FMargolin, Kim APlimack, Elizabeth RLambert, Alexandre MWaxman, Ian M and Hammers, Hans J
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 33, (no. 13), pp. 1430-1437, May 1, 2015. | Journal Article
 
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Amin, AsimDudek, Arkadiusz ZLogan, Theodore FLance, Raymond SHolzbeierlein, Jeffrey MKnox, Jennifer JMaster, Viraj APal, Sumanta KMiller, Wilson HKarsh, Lawrence ITcherepanova, Irina YDeBenedette, Mark AWilliams, W LeePlessinger, Douglas CNicolette, Charles A and Figlin, Robert A
Journal for immunotherapy of cancer, vol. 3, pp. 14, 2015. | Journal Article
 
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott, David FMc Dermott, David FCheng, Su-ChunCheng, Su-ChunSignoretti, SabinaSignoretti, SabinaMargolin, Kim AMargolin, Kim AClark, Joseph IClark, Joseph ISosman, Jeffrey ASosman, Jeffrey ADutcher, Janice PDutcher, Janice PLogan, Theodore FLogan, Theodore FCurti, Brendan DCurti, Brendan DErnstoff, Marc SErnstoff, Marc SAppleman, LeonardAppleman, LeonardWong, Michael K KWong, Michael K KKhushalani, Nikhil IKhushalani, Nikhil IOleksowicz, LeslieOleksowicz, LeslieVaishampayan, Ulka NVaishampayan, Ulka NMier, James WMier, James WPanka, David JPanka, David JBhatt, Rupal SBhatt, Rupal SBailey, Alexandra SBailey, Alexandra SLeibovich, Bradley CLeibovich, Bradley CKwon, Eugene DKwon, Eugene DKabbinavar, Fairooz FKabbinavar, Fairooz FBelldegrun, Arie SBelldegrun, Arie SFiglin, Robert AFiglin, Robert APantuck, Allan JPantuck, Allan JRegan, Meredith MRegan, Meredith MAtkins, Michael B and Atkins, Michael B
Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 21, (no. 3), pp. 561-568, February 1, 2015. | Journal Article
 
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC)
Plimack, Elizabeth RHammers, Hans JRini, Brian IMcDermott, David FRedman, BruceKuzel, TimothyHarrison, Michael RogerVaishampayan, Ulka NDrabkin, Harry AGeorge, SabyLogan, Theodore FMargolin, Kim AllysonXu, Li-anWaxman, Ian and Motzer, Robert
Journal of Clinical Oncology, vol. 33, (no. 15_suppl), pp. 4553, 2015-05-20. | Journal Article
 
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
Fletcher, James WFletcher, James WLogan, Theodore FLogan, Theodore FEitel, Jacob AEitel, Jacob AMathias, Carla JMathias, Carla JNg, YenNg, YenLacy, Jeffrey LLacy, Jeffrey LHutchins, Gary DHutchins, Gary DGreen, Mark A and Green, Mark A
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 56, (no. 1), pp. 56-62, January 2015. | Journal Article
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Clark, JosephClark, JosephFlaherty, LawrenceFlaherty, LawrenceErnstoff, MarcErnstoff, MarcKoon, HenryKoon, HenryMilhem, MohammedMilhem, MohammedMilitello, GeraldMilitello, GeraldAgarwala, SanjivAgarwala, SanjivCurti, BrendanCurti, BrendanCranmer, LeeCranmer, LeeLao, ChristopherLao, ChristopherLogan, TheodoreLogan, TheodoreLutzky, JoseLutzky, JoseRudrapatna, VenkateshRudrapatna, VenkateshDaniels, GregoryDaniels, GregoryTaback, BretTaback, BretAung, SandraAung, SandraLowder, JamesLowder, JamesLawson, David and Lawson, David
2014. | Journal Article
 
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Clark, JosephClark, JosephFlaherty, LawrenceFlaherty, LawrenceErnstoff, MarcErnstoff, MarcKoon, HenryKoon, HenryMilhem, MohammedMilhem, MohammedMilitello, GeraldMilitello, GeraldAgarwala, SanjivAgarwala, SanjivCurti, BrendanCurti, BrendanCranmer, LeeCranmer, LeeLao, Christopher DLao, Christopher DLogan, Theodore FLogan, Theodore FLutzky, JoseLutzky, JoseRudrapatna, VenkateshRudrapatna, VenkateshDaniels, GregoryDaniels, GregoryTaback, BretTaback, BretAung, SandraAung, SandraLowder, JamesLowder, JamesLawson, David and Lawson, David
Journal for ImmunoTherapy of Cancer, vol. 2, (no. Suppl 3), pp. P77, 2014-00-00. | Journal Article
 
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas, AntoniGonzalez, RenePavlick, AnnaHamid, OmidGajewski, Thomas FDaud, AdilFlaherty, LawrenceLogan, TheodoreChmielowski, BartoszLewis, KarlKee, DamienBoasberg, PeterYin, MingChan, IrisMusib, LunaChoong, NicholasPuzanov, Igor and Mc Arthur, Grant A
The Lancet. Oncology, vol. 15, (no. 9), pp. 954-965, August 2014. | Journal Article
 
Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib
Amin, AsimDudek, Arkadiusz ZLogan, Theodore FLance, Raymond SHolzbeierlein, Jeffrey MMaster, Viraj APal, Sumanta KumarKnox, Jennifer JKarsh, Lawrence IvanPlessinger, DougNicolette, Charles A and Figlin, Robert A
Journal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 4524, 2014-05-20. | Journal Article
 
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study
Ashraf, MadeehaAshraf, MadeehaKirkwood, John MKirkwood, John MErnstoff, Marc SErnstoff, Marc STawbi, Hussein Abdul HassanTawbi, Hussein Abdul-HassanFrankel, Paul HenryFrankel, Paul HenryRuel, NoraRuel, NoraKendra, Kari LynnKendra, Kari LynnOlencki, ThomasOlencki, ThomasKhushalani, Nikhil IKhushalani, Nikhil ILogan, Theodore FLogan, Theodore FMargolin, Kim AllysonMargolin, Kim AllysonChen, Alice PChen, Alice PTarhini, Ahmad A and Tarhini, Ahmad A
Journal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. TPS9120, 2014-05-20. | Journal Article
 
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial
Motzer, Robert JRini, Brian IMcDermott, David FRedman, Bruce GKuzel, TimothyHarrison, Michael RogerVaishampayan, Ulka NDrabkin, Harry AGeorge, SabyLogan, Theodore FMargolin, Kim AllysonPlimack, Elizabeth RWaxman, IanLambert, Alexandre and Hammers, Hans J
Journal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 5009, 2014-05-20. | Journal Article
 
PET/CT assessment of tumor perfusion in metastatic renal cell carcinoma (RCC) before and during sunitinib: A comparison of 15O-water with 62Cu-ETS
Logan, Theodore FLogan, Theodore FLogan, Theodore FFletcher, James WFletcher, James WFletcher, James WGreen, Mark AGreen, Mark AGreen, Mark AEitel, Jacob AaronEitel, Jacob AaronEitel, Jacob AaronHutchins, GaryHutchins, Gary and Hutchins, Gary
Journal of Clinical Oncology, vol. 32, (no. 15_suppl), pp. 11110, 2014-05-20. | Journal Article
 
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Lam, Elaine TLam, Elaine TWong, Michael K KWong, Michael K KAgarwal, NeerajAgarwal, NeerajRedman, Bruce GRedman, Bruce GLogan, TheodoreLogan, TheodoreGao, DexiangGao, DexiangFlaig, Thomas WFlaig, Thomas WLewis, KarlLewis, KarlPoust, JamiePoust, JamieMonk, PaulMonk, PaulJarkowski, AnthonyJarkowski, AnthonySendilnathan, ArunSendilnathan, ArunBolden, MarcusBolden, MarcusKuzel, Timothy MKuzel, Timothy MOlencki, Thomas and Olencki, Thomas
Journal of immunotherapy (Hagerstown, Md. : 1997), vol. 37, (no. 7), pp. 360-365, September 2014. | Journal Article
2013
A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial
Sarantopoulos, JohnDang, Long HLauer, Richard CStarodub, AlexanderHauke, Ralph JGalsky, Matt DBylow, Kathryn ACowey, Charles LanceBibby, David CKremmidiotis, GabrielDoolin, Elizabeth ELavranos, Tina CIglesias, Jose LuisSonpavde, GuruLogan, TheodoreHahn, Noah MSweeney, Christopher and Hutson, Thomas E
Journal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. 4563, 2013-05-20. | Journal Article
 
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)
Melero, IgnacioGangadhar, Tara CKohrt, Holbrook EdwinSegal, Neil HowardLogan, TheodoreUrba, Walter JohnHodi, F. StephenOtt, Patrick AlexanderPerez-Gracia, Jose LuisWolchok, Jedd DShah, AadharKurland, John FCohen, Lewis JLevy, RonaldWigginton, Jon M and Goldberg, Stacie M
Journal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3107, 2013-05-20. | Journal Article
 
Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.
Logan, Theodore F
Current oncology reports, vol. 15, (no. 2), pp. 83-90, 2013/Apr. | Journal Article
 
Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies
Bailey, Alexandra SCheng, SuChunKwon, Eugene DLeibovich, Bradley CSignoretti, SabinaDutcher, Janice PAppleman, Leonard JosephSosman, Jeffrey AlanMargolin, Kim AllysonClark, JosephKhushalani, Nikhil ICurti, Brendan DErnstoff, Marc SPantuck, Allan JVaishampayan, Ulka NLogan, TheodoreMcDermott, David F and Atkins, Michael B
Journal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. 4521, 2013-05-20. | Journal Article
 
Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM)
Bhatia, ShailenderCurti, Brendan DGordon, Michael SChesney, JasonLogan, TheodoreThompson, John ARoyer, NelsBittner, RachelFontana, DavidGrosso, JosephClemens, Pamela LCohen, Lewis JAhlers, Christoph MatthiasWigginton, Jon M and Hwu, Patrick
Journal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3109, 2013-05-20. | Journal Article
 
Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors
Chow, Laura Quan ManGordon, Michael SLogan, Theodore FAntonia, Scott JBhatia, ShailenderThompson, John ABrahmer, Julie RSolberg, GretchenBittner, RachelFontana, DavidGrosso, JosephCohen, Lewis JAhlers, Christoph MatthiasWigginton, Jon M and Drake, Charles G
Journal of Clinical Oncology, vol. 31, (no. 15_suppl), pp. TPS3112, 2013-05-20. | Journal Article
 
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri, ToniVaishampayan, UlkaRosenberg, Jonathan ELogan, Theodore FHarzstark, Andrea LBukowski, RonaldRini, Brian ISrinivas, SandhyaStein, Mark NAdams, Laurel MOttesen, Lone HLaubscher, Kevin HSherman, LaurieMc Dermott, David FHaas, Naomi BFlaherty, KeithRoss, RobertEisenberg, PeterMeltzer, Paul SMerino Neumann, Maria JBottaro, DonLinehan, W M and Srinivasan, Ramaprasad
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, (no. 2), pp. 181-6, 2013/Jan/10. | Journal Article
 
Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)
Amin, AsimDudek, ArkadiuszLogan, TheodoreLance, Raymond SHolzbeierlein, Jeffrey MMaster, Viraj APal, Sumanta KumarKnox, Jennifer JKarsh, Lawrence IvanPlessinger, DougNicolette, Charles A and Figlin, Robert A
Journal of Clinical Oncology, vol. 31, (no. 6_suppl), pp. 357, 2013-02-20. | Journal Article
 
Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC)
Hutson, Thomas EDang, Long HLauer, Richard CStarodub, AlexanderHauke, Ralph JGalsky, Matt DBylow, Kathryn ACowey, Charles LanceBibby, David CKremmidiotis, GabrielDoolin, Elizabeth ELavranos, Tina CSonpavde, GuruLogan, TheodoreHahn, Noah MSweeney, Christopher and Sarantopoulos, John
Journal of Clinical Oncology, vol. 31, (no. 6_suppl), pp. 397, 2013-02-20. | Journal Article